AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31956341 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic foot ulcer treatment
Number of subjects: 129
Study 31956422 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide
Number of subjects: 1071
Study 31956422 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1071
Study 31956421 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic LED lighting for 4 weeks in addition to standard treatment
Number of subjects: 0
Study 31956421 — intervention group
Group type: COMPARATOR
Intervention: Static LED lighting for 4 weeks in addition to standard treatment
Number of subjects: 0
Study 31956433 — intervention group
Group type: EXPERIMENTAL
Intervention: Real long-wave diathermy (LWD)
Number of subjects: 0
Study 31956433 — intervention group
Group type: COMPARATOR
Intervention: Sham long-wave diathermy (sham LWD)
Number of subjects: 0
Study 31956433 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual massage
Number of subjects: 0
Study 31956432 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ziv-aflibercept (IVZ) 1.25 mg
Number of subjects: 21
Study 31956723 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavior therapy (CBT)
Number of subjects: 0
Study 31956723 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31956726 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated Tobacco Products (HTPs)
Number of subjects: 220
Study 31956726 — intervention group
Group type: COMPARATOR
Intervention: Electronic Cigarettes (ECs)
Number of subjects: 220
Study 31956893 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty (≥3 domains present)
Number of subjects: 1148
Study 31956893 — intervention group
Group type: COMPARATOR
Intervention: Prefrail (1-2 domains present)
Number of subjects: 1148
Study 31956893 — intervention group
Group type: COMPARATOR
Intervention: Robust (0 domains present)
Number of subjects: 1148
Study 31956961 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg tofogliflozin
Number of subjects: 40
Study 31956961 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg glimepiride
Number of subjects: 40
Study 31957634 — intervention group
Group type: EXPERIMENTAL
Intervention: E-CABG DSWI score (risk score for deep sternal wound infection)
Number of subjects: 7352
Study 31957634 — intervention group
Group type: EXPERIMENTAL
Intervention: E-CABG DSWI score
Number of subjects: 7352
Study 31957639 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with DOA
Number of subjects: 104
Study 31957639 — intervention group
Group type: COMPARATOR
Intervention: Control patients
Number of subjects: 104
Study 31958096 — intervention group
Group type: EXPERIMENTAL
Intervention: DA-CH5
Number of subjects: 0
Study 31958302 — intervention group
Group type: EXPERIMENTAL
Intervention: NGT-1-hour-high (glucose ≥8.6 mmol/L)
Number of subjects: 434
Study 31958302 — intervention group
Group type: COMPARATOR
Intervention: NGT-1-hour-normal (glucose <8.6 mmol/L)
Number of subjects: 434
Study 31958302 — intervention group
Group type: COMPARATOR
Intervention: NGT group
Number of subjects: 434
Study 31958302 — intervention group
Group type: COMPARATOR
Intervention: Pre-diabetes group
Number of subjects: 434
Study 31958302 — intervention group
Group type: COMPARATOR
Intervention: Diabetes group
Number of subjects: 434
Study 31958302 — intervention group
Group type: EXPERIMENTAL
Intervention: One-hour glucose concentration ≥8.6 mmol/L
Number of subjects: 434
Study 31958308 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 BGMS (including ABRA, Accu-Chek Guide, AURUM, etc.)
Number of subjects: 100
Study 31958308 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 BGMS (including ABRA, Accu-Chek Guide, AURUM, etc.)
Number of subjects: 100
Study 31958308 — intervention group
Group type: EXPERIMENTAL
Intervention: All tested BGMS
Number of subjects: 100
Study 31958310 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic change in fetuin-A levels from the first to the second trimester
Number of subjects: 270
Study 31958310 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of the increase in fetuin-A concentration from the first to the second trimester
Number of subjects: 270
Study 31958310 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in fetuin-A concentration
Number of subjects: 270
Study 31958884 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplantation (FMT)
Number of subjects: 174
Study 31959034 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline-based regimens
Number of subjects: 323
Study 31959034 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnT levels >14 ng/L at anthracycline completion
Number of subjects: 323
Study 31959034 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 323
Study 31959034 — intervention group
Group type: EXPERIMENTAL
Intervention: Myeloperoxidase
Number of subjects: 323
Study 31959059 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Number of subjects: 120
Study 31959059 — intervention group
Group type: COMPARATOR
Intervention: High ligation and stripping
Number of subjects: 120
Study 31959059 — intervention group
Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 120
Study 31959135 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroticism
Number of subjects: 429
Study 31959135 — intervention group
Group type: EXPERIMENTAL
Intervention: Model
Number of subjects: 429
Study 31959135 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived stress and cognitive function
Number of subjects: 429
Study 31959168 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients not considering pain as a warning signal (43.2% had a favourable functional improvement of ≥30% on the RMDQ)
Number of subjects: 816
Study 31959168 — intervention group
Group type: COMPARATOR
Intervention: Patients considering pain a warning signal (41.2% had a favourable functional improvement of ≥30% on the RMDQ)
Number of subjects: 816
Study 31959168 — intervention group
Group type: EXPERIMENTAL
Intervention: STarT Back Tool high-risk patients
Number of subjects: 816
Study 31959168 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic pain
Number of subjects: 816
Study 31959168 — intervention group
Group type: EXPERIMENTAL
Intervention: Beliefs about finding the cause, diagnostic imaging, perceiving to have received advice to stay active, or pain intensity
Number of subjects: 816
Study 31959169 — intervention group
Group type: EXPERIMENTAL
Intervention: PC-PA quadrant affiliation
Number of subjects: 283
Study 31959169 — intervention group
Group type: EXPERIMENTAL
Intervention: PC-PA quadrants characterization
Number of subjects: 283
Study 31959169 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical characteristics assessment
Number of subjects: 283
Study 31959169 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of physical activity (PA)
Number of subjects: 283
Study 31959346 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib 960 mg twice daily
Number of subjects: 118
Study 31959428 — intervention group
Group type: EXPERIMENTAL
Intervention: Edwards Sapien 3 BE-THV with severe LZC
Number of subjects: 350
Study 31959428 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon predilatation (BPreD) in patients with severe LZC
Number of subjects: 350
Study 31959428 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe LVOTC
Number of subjects: 350
Study 31959583 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective social support
Number of subjects: 0
Study 31959583 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived stressfulness
Number of subjects: 0
Study 31959583 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative coping style
Number of subjects: 0
Study 31959583 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived stressfulness mediating effect
Number of subjects: 0
Study 31959650 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 0
Study 31959650 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31959735 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-resistant target genes and genes associated with poor prognosis
Number of subjects: 156
Study 31959735 — intervention group
Group type: EXPERIMENTAL
Intervention: ssGSEA analysis
Number of subjects: 156
Study 31959735 — intervention group
Group type: EXPERIMENTAL
Intervention: TMB analysis
Number of subjects: 156
Study 31959992 — intervention group
Group type: EXPERIMENTAL
Intervention: Hu19-CD828Z T cells
Number of subjects: 20
Study 31959992 — intervention group
Group type: COMPARATOR
Intervention: FMC63-28Z T cells
Number of subjects: 20
Study 31960250 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Sclerosis (MS) patients
Number of subjects: 1663
Study 31960250 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromyelitis Optica Spectrum Disorder (NMOSD) patients
Number of subjects: 1663
Study 31960589 — intervention group
Group type: EXPERIMENTAL
Intervention: Online group (online counselling and online, supervised, HIV self-testing)
Number of subjects: 564
Study 31960589 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed group (online pre-test counselling and offline HIV testing)
Number of subjects: 564
Study 31960589 — intervention group
Group type: EXPERIMENTAL
Intervention: Offline group (offline HIV counselling and testing)
Number of subjects: 564
Study 31960589 — intervention group
Group type: COMPARATOR
Intervention: Online group
Number of subjects: 564
Study 31960589 — intervention group
Group type: COMPARATOR
Intervention: <17 years old at first sex
Number of subjects: 564
Study 31960589 — intervention group
Group type: COMPARATOR
Intervention: Amphetamine-type stimulants use in the past six months
Number of subjects: 564
Study 31960589 — intervention group
Group type: COMPARATOR
Intervention: No/single sex partner in the past six months
Number of subjects: 564
Study 31960816 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelial progenitor cells (EPCs) counted with flow cytometry, assessed at baseline, days 7, 30, and 90.
Number of subjects: 100
Study 31960816 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in circulating EPC numbers and/or functional capacity.
Number of subjects: 100
Study 31960953 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroperative carcinoembryonic antigen (CEA)-specific fluorescence imaging during cytoreductive surgery-hyperthermic intraperitoneal chemotherapy
Number of subjects: 14
Study 31960953 — intervention group
Group type: EXPERIMENTAL
Intervention: SGM-101
Number of subjects: 14
Study 31961057 — intervention group
Group type: EXPERIMENTAL
Intervention: Nano+™ stent implantation
Number of subjects: 2481
Study 31961331 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth self-management intervention (EPIO) including one face-to-face introduction session and 9 app-based educational and exercise-based modules
Number of subjects: 53
Study 31961331 — intervention group
Group type: EXPERIMENTAL
Intervention: Stakeholder input and user-centered design approach
Number of subjects: 53
Study 31961766 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib plus pembrolizumab (200 mg intravenously every 3 weeks)
Number of subjects: 137
Study 31961766 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib 20 mg/d plus pembrolizumab (recommended phase II dose)
Number of subjects: 137
Study 31961766 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib 24 mg/d plus pembrolizumab (initial dose level)
Number of subjects: 137
Study 31961766 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent dose-de-escalation cohort (lenvatinib 20 mg/d plus pembrolizumab)
Number of subjects: 137
Study 31961822 — intervention group
Group type: EXPERIMENTAL
Intervention: G6PD-deficient RBCs
Number of subjects: 37
Study 31961822 — intervention group
Group type: COMPARATOR
Intervention: G6PD-normal RBCs
Number of subjects: 37
Study 31961826 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg mirabegron for 4 weeks
Number of subjects: 14
Study 31961829 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron treatment
Number of subjects: 0
Study 31961829 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioned media from adipocytes treated with mirabegron
Number of subjects: 0
Study 31963294 — intervention group
Group type: EXPERIMENTAL
Intervention: RNA sequencing of 12 ccRCC patients with aggressive characteristics
Number of subjects: 24
Study 31963294 — intervention group
Group type: COMPARATOR
Intervention: RNA sequencing of 12 matched ccRCC patients without aggressive characteristics
Number of subjects: 24
Study 31964290 — intervention group
Group type: EXPERIMENTAL
Intervention: Early initiation of DOACs (≤3 days after stroke onset)
Number of subjects: 1192
Study 31964290 — intervention group
Group type: COMPARATOR
Intervention: Late initiation of DOACs (≥4 days after stroke onset)
Number of subjects: 1192
Study 31964386 — intervention group
Group type: EXPERIMENTAL
Intervention: Boys
Number of subjects: 671
Study 31964386 — intervention group
Group type: EXPERIMENTAL
Intervention: Girls
Number of subjects: 671
Study 31964386 — intervention group
Group type: COMPARATOR
Intervention: Boys and Girls
Number of subjects: 671
Study 31964391 — intervention group
Group type: EXPERIMENTAL
Intervention: Care Coordination Instrument (CCI)
Number of subjects: 140
Study 31964568 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiral-Z iliac leg graft
Number of subjects: 599
Study 31964784 — intervention group
Group type: EXPERIMENTAL
Intervention: CUE-101, a novel therapeutic fusion protein composed of a human leukocyte antigen (HLA) complex, an HPV16 E7 peptide epitope, reduced affinity human IL2 molecules, and an effector attenuated human IgG1 Fc domain.
Number of subjects: 0
Study 31964784 — intervention group
Group type: EXPERIMENTAL
Intervention: CUE-101
Number of subjects: 0
Study 31965161 — intervention group
Group type: EXPERIMENTAL
Intervention: High Hemoglobin Glycation Index (HGI) subgroup
Number of subjects: 6829
Study 31965161 — intervention group
Group type: EXPERIMENTAL
Intervention: Low to high HGI subgroups
Number of subjects: 6829
Study 31965161 — intervention group
Group type: EXPERIMENTAL
Intervention: High HGI
Number of subjects: 6829
Study 31965161 — intervention group
Group type: COMPARATOR
Intervention: HbA1c
Number of subjects: 6829
Study 31965161 — intervention group
Group type: COMPARATOR
Intervention: FPG and 2hPG
Number of subjects: 6829
Study 31965820 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 31967219 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintendo WiiTM gaming system
Number of subjects: 60
Study 31967304 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant hCG 250 μg
Number of subjects: 160
Study 31967355 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphodiesterase 10A PET imaging
Number of subjects: 45
Study 31967355 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (N=45)
Number of subjects: 45
Study 31969132 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous harness-supported treadmill training in a room cooled to 16 °C (10 weeks; 3 times/week)
Number of subjects: 10
Study 31969132 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous harness-supported treadmill training
Number of subjects: 10
Study 31969330 — intervention group
Group type: EXPERIMENTAL
Intervention: ABBV-838 (3+3 design) intravenously starting from 0.6 mg/kg up to 6.0 mg/kg for 3-week dosing intervals (Q3W), continued for up to 24 months.
Number of subjects: 75
Study 31969335 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab plus nivolumab
Number of subjects: 32
Study 31969338 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine and Vorinostat with chemotherapy (vincristine, dexamethasone, mitoxantrone, PEG-asparaginase)
Number of subjects: 23
Study 31969366 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diabetes prevention programme (LC-DPP)
Number of subjects: 21
Study 31970051 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-level CDA
Number of subjects: 942
Study 31970051 — intervention group
Group type: COMPARATOR
Intervention: 2-level CDA
Number of subjects: 942
Study 31970051 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-level ACDF
Number of subjects: 942
Study 31970051 — intervention group
Group type: COMPARATOR
Intervention: 2-level ACDF
Number of subjects: 942
Study 31970446 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower MRC sum score at ICU discharge
Number of subjects: 883
Study 31970446 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal CMAP
Number of subjects: 883
Study 31970446 — intervention group
Group type: EXPERIMENTAL
Intervention: MRC in MRC&CMAP-cohort
Number of subjects: 883
Study 31970446 — intervention group
Group type: EXPERIMENTAL
Intervention: Low MRC in survivors
Number of subjects: 883
Study 31970446 — intervention group
Group type: EXPERIMENTAL
Intervention: MRC ≤ 55
Number of subjects: 883
Study 31970594 — intervention group
Group type: EXPERIMENTAL
Intervention: WBRT with SIB (25 or 37.5 Gy WBRT + 45 or 52.5 Gy SIB to gross lesions in 10 or 15 fractions)
Number of subjects: 13
Study 31970894 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin Mark clipped Axillary nodes Removal Technique (SMART)
Number of subjects: 14
Study 31971541 — intervention group
Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec (T-VEC) plus pembrolizumab (200-mg flat dose) intravenously; T-VEC first dose ≤4 mL × 106 PFU/mL, subsequent doses ≤4 mL × 108 PFU/mL, injected into palpable tumor site(s) on day 1 of each 21-day cycle.
Number of subjects: 20
Study 31971541 — intervention group
Group type: EXPERIMENTAL
Intervention: T-VEC plus pembrolizumab
Number of subjects: 20
Study 31971567 — intervention group
Group type: EXPERIMENTAL
Intervention: IV posaconazole 300 mg
Number of subjects: 24
Study 31971567 — intervention group
Group type: EXPERIMENTAL
Intervention: IV posaconazole 400 mg
Number of subjects: 24
Study 31971567 — intervention group
Group type: EXPERIMENTAL
Intervention: IV posaconazole
Number of subjects: 24
Study 31971890 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphedema Functioning, Disability, and Health Questionnaire
Number of subjects: 0
Study 31972008 — intervention group
Group type: EXPERIMENTAL
Intervention: rs9349379-G allele
Number of subjects: 185
Study 31972008 — intervention group
Group type: EXPERIMENTAL
Intervention: Zibotentan (ETA antagonist)
Number of subjects: 185
Study 31972008 — intervention group
Group type: COMPARATOR
Intervention: Contemporary reference genome bank control subjects
Number of subjects: 185
Study 31972009 — intervention group
Group type: EXPERIMENTAL
Intervention: ST2 (>26 ng/mL) in children age 10 years or younger
Number of subjects: 415
Study 31972009 — intervention group
Group type: EXPERIMENTAL
Intervention: TNFR1 (>3441 pg/mL) in children age 10 years or younger
Number of subjects: 415
Study 31972009 — intervention group
Group type: EXPERIMENTAL
Intervention: REG3α (>25 ng/mL) in children age 10 years or younger
Number of subjects: 415
Study 31972009 — intervention group
Group type: EXPERIMENTAL
Intervention: ST2 (>26 ng/mL) in patients older than age 10 years
Number of subjects: 415
Study 31972009 — intervention group
Group type: EXPERIMENTAL
Intervention: TNFR1 (>3441 pg/mL) in patients older than age 10 years
Number of subjects: 415
Study 31972009 — intervention group
Group type: EXPERIMENTAL
Intervention: REG3α (>25 ng/mL) in patients older than age 10 years
Number of subjects: 415
Study 31972009 — intervention group
Group type: EXPERIMENTAL
Intervention: ST2 before HCT in children age 10 years or younger
Number of subjects: 415
Study 31972009 — intervention group
Group type: EXPERIMENTAL
Intervention: ST2, TNFR1, and REG3α in the first 3 weeks after HCT
Number of subjects: 415
Study 31972476 — intervention group
Group type: EXPERIMENTAL
Intervention: Norditropin® (somatropin; Novo Nordisk A/S, Denmark) administered at the discretion of the treating physician.
Number of subjects: 3180
Study 31972476 — intervention group
Group type: EXPERIMENTAL
Intervention: NordiNet® IOS (n=971) and ANSWER (n=304) studies data.
Number of subjects: 3180
Study 31972852 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone mHealth application
Number of subjects: 10
Study 31972852 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable tracking device (Apple watch)
Number of subjects: 10
Study 31972852 — intervention group
Group type: EXPERIMENTAL
Intervention: Both mHealth technologies
Number of subjects: 10
Study 31973598 — intervention group
Group type: EXPERIMENTAL
Intervention: Live video-supervised exercise (3 times/week) and nutrition sessions (1 time/week) during the 12-16 week intervention phase
Number of subjects: 14
Study 31973598 — intervention group
Group type: EXPERIMENTAL
Intervention: Live video-supervised exercise and nutrition sessions during the 12-16 week maintenance phase (1 time/week) and self-directed exercise sessions (2 times/week)
Number of subjects: 14
Study 31973779 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-blood PUFA assessment
Number of subjects: 174
Study 31973779 — intervention group
Group type: EXPERIMENTAL
Intervention: Total PUFA
Number of subjects: 174
Study 31973779 — intervention group
Group type: EXPERIMENTAL
Intervention: n-6 PUFA
Number of subjects: 174
Study 31973779 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 long-chain PUFA (LCPUFA)
Number of subjects: 174
Study 31973779 — intervention group
Group type: EXPERIMENTAL
Intervention: MA:AA ratio
Number of subjects: 174
Study 31973779 — intervention group
Group type: EXPERIMENTAL
Intervention: Linoleic acid
Number of subjects: 174
Study 31973779 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocyte counts
Number of subjects: 174
Study 31973980 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavum septum pellucidum (CSP) volume
Number of subjects: 171
Study 31973980 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippocampal volume
Number of subjects: 171
Study 31974103 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 0
Study 31974140 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity troponin T (hsTNT)
Number of subjects: 51
Study 31974140 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminal pro-brain natriuretic peptide serum levels
Number of subjects: 51
Study 31974140 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 Tesla (3T) magnetic resonance neurography (MRN)
Number of subjects: 51
Study 31974140 — intervention group
Group type: COMPARATOR
Intervention: Control group (subjects without diabetes)
Number of subjects: 51
Study 31974144 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon at high physiological levels
Number of subjects: 30
Study 31974144 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon at basal levels
Number of subjects: 30
Study 31974144 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy lean participants)
Number of subjects: 30